KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Shares Outstanding (Weighted Average) (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Shares Outstanding (Weighted Average) for 12 consecutive years, with $79.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 1.95% to $79.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $79.2 million, a 1.95% increase, with the full-year FY2024 number at $77.9 million, up 16.45% from a year prior.
  • Shares Outstanding (Weighted Average) was $79.2 million for Q3 2025 at Xenon Pharmaceuticals, roughly flat from $79.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $79.2 million in Q3 2025 to a low of $36.8 million in Q1 2021.
  • A 5-year average of $63.5 million and a median of $65.9 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 48.96% in 2022, then rose 1.41% in 2025.
  • Xenon Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $43.6 million in 2021, then surged by 38.77% to $60.5 million in 2022, then grew by 10.48% to $66.9 million in 2023, then rose by 16.45% to $77.9 million in 2024, then grew by 1.74% to $79.2 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Shares Outstanding (Weighted Average) are $79.2 million (Q3 2025), $79.0 million (Q2 2025), and $78.7 million (Q1 2025).